Pediatric brain tumors and cerebrovascular disorders are two different sets of diseases however they share some similarities, such as vascular anomalies and challenging early detection.

Ed Smith's lab is interested in Axon Guidance Factors as targets and biomarkers for these pathologies. As a postdoc fellow in the Smith lab, and thanks to her expertise in Neuro-Oncology, Julie's main project focuses on the involvement of the Netrins' family in the invasion and angiogenesis of pediatric brain tumors. She performs orthotopic xenografts of brain tumor cells in mice to study tumor growth and invasiveness in response to different treatments.

Julie has also developed her expertise in Vascular Biology and works on the role of Ephrins in cerebrovascular diseases, such as AVM, Moyamoya, or Cavernous Malformations.

Ultimately, the goal of these scientific projects would be to detect these diseases earlier, thanks to new biomarkers, and to be able to treat them with the discovery and development of new therapeutic targets.


Julie Sesen obtained her Ph.D. in Oncology in 2013 at the Cancer Research Center of Toulouse in France. Her research in Pr. Elizabeth Moyal and Dr. Nicolas Skuli's lab focused on the role of translation initiation factors in the proliferation and radioresistance of glioblastoma.

In 2017, Julie joined the lab of Edward Smith, MD., Ph.D. as a Research Fellow at the Vascular Biology Program, Boston Children's Hospital. She leads different research projects and collaborations and has expertise in mentoring research assistants.

Julie is member of the board of the BCH Postdoc Association since November 2017 and she is now the co-Chair of the Public Affairs committee and the treasurer of the Postdoc Association. Besides research, Julie loves latin music and dances. She also loves exploring new areas around Boston and traveling around the world.


Publications powered by Harvard Catalyst Profiles

  1. 5' Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints. Cancers (Basel). 2021 Jun 25; 13(13). View abstract
  2. Non-invasive Urinary Biomarkers in Moyamoya Disease. Front Neurol. 2021; 12:661952. View abstract
  3. Neogenin is highly expressed in diffuse intrinsic pontine glioma and influences tumor invasion. Brain Res. 2021 07 01; 1762:147348. View abstract
  4. Translation reprogramming by eIF3 linked to glioblastoma resistance. NAR Cancer. 2020 Sep; 2(3):zcaa020. View abstract
  5. Dysregulation of the EphrinB2-EphB4 ratio in pediatric cerebral arteriovenous malformations is associated with endothelial cell dysfunction in vitro and functions as a novel noninvasive biomarker in patients. Exp Mol Med. 2020 04; 52(4):658-671. View abstract
  6. Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors. Oncotarget. 2018 Jan 30; 9(8):8054-8067. View abstract
  7. Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. Oncotarget. 2017 Oct 17; 8(49):86947-86968. View abstract
  8. The Bad, the Good and eIF3e/INT6. Front Biosci (Landmark Ed). 2017 01 01; 22:1-20. View abstract
  9. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene. 2017 05 25; 36(21):3037-3047. View abstract
  10. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS One. 2015; 10(4):e0123721. View abstract
  11. The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability. Blood. 2015 May 21; 125(21):3263-72. View abstract
  12. Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells. Int J Mol Sci. 2014 Jan 29; 15(2):2172-90. View abstract